Wipfli Financial Advisors’s Intellia Therapeutics NTLA Stock Holding History

Wipfli Financial Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$25K	Buy	+455	New	+$28.2K	﹤0.01%	1473

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wipfli Financial Advisors's NTLA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Intellia Therapeutics (NTLA) in Q3 2022: 455 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1473 among its holdings.

319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Wipfli Financial Advisors held 455 shares of Intellia Therapeutics worth $25K as of Q3 2022.
Intellia Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Intellia Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1473 holding.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.